Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Annales D'Endocrinologie
|
August 29, 2018
Expert opinions on adrenal complications in immunotherapy
M Haissaguerre, S Hescot, J Bertherat, et al.
Annales D'Endocrinologie
|
December 21, 2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology]
S Hescot, E Baudin, F Borson-Chazot, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
September 6, 2015
[Tumor-to-tumor metastasis in a renal carcinoma: A rare and surprising event]
T Chanu, C S Pavel, M-H Saint-Frison, et al.
Journal of Endocrinological Investigation
|
August 22, 2024
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network
M Faron, A Naman, J Delahousse, et al.
Endocrine
|
March 10, 2020
Locally unresectable differentiated thyroid cancer: outcomes and perspectives
L Lamartina, Y Godbert, C Nascimento, et al.
Endocrine-Related Cancer
|
November 8, 2018
French Endocrine Society Guidance on endocrine side effects of immunotherapy
F Castinetti, F Albarel, F Archambeaud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
A Moreira, J Masliah-Planchon, C Callens, et al.
ESMO Open
|
March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET
J Hadoux, J Hernando, K H Wong, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
K Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Annales D'Endocrinologie
|
August 29, 2018
Expert opinions on adrenal complications in immunotherapy
M Haissaguerre, S Hescot, J Bertherat, et al.
Annales D'Endocrinologie
|
December 21, 2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology]
S Hescot, E Baudin, F Borson-Chazot, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
September 6, 2015
[Tumor-to-tumor metastasis in a renal carcinoma: A rare and surprising event]
T Chanu, C S Pavel, M-H Saint-Frison, et al.
Journal of Endocrinological Investigation
|
August 22, 2024
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network
M Faron, A Naman, J Delahousse, et al.
Endocrine
|
March 10, 2020
Locally unresectable differentiated thyroid cancer: outcomes and perspectives
L Lamartina, Y Godbert, C Nascimento, et al.
Endocrine-Related Cancer
|
November 8, 2018
French Endocrine Society Guidance on endocrine side effects of immunotherapy
F Castinetti, F Albarel, F Archambeaud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
A Moreira, J Masliah-Planchon, C Callens, et al.
ESMO Open
|
March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET
J Hadoux, J Hernando, K H Wong, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
K Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Page
of 1